

Recipharm in discussions with Alcon regarding long-term manufacturing agreement

Recipharm is currently in discussions with Alcon and has reached agreement in principle to enter into a long-term manufacturing agreement for a range of ophthalmology products. As part of this arrangement, Recipharm will also acquire Alcon's manufacturing facility located in Kaysersberg, France. The 260 people currently employed at the Kaysersberg site would transfer and continue to be offered employment by Recipharm following the date of the sale. Further details will be made available following the end of consultation with the Works Council of Alcon and finalisation of the negotiations.

For more information please visit www.recipharm.com or contact:

Björn Westberg, CFO, bjorn.westberg@recipharm.com, +46 8 602 46 20

Mark Quick, EVP Corporate Development, mark.quick@recipharm.com, +44 1 925714263

This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. This information was submitted for publication on 7 September 2015, at 08:30 am CET.

About Recipharm

Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm's turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com